PepStar Therapeutics

Explore the latest insights on PepStar Therapeutics and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of PepStar Therapeutics’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide
CompanyDeals

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has entered into a definitive agreement with PepStar Therapeutics Limited to acquire its lead asset, HCXT‑2001, an investigational Phase I oral IL‑23…

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea

Everest Medicines Secures TFDA Approval for Velsipity (etrasimod) in Ulcerative Colitis – Completion of All Authorized Territories Across Greater China and South Korea

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia

Patronus Biotech Secures Ethics Approval to Launch Phase I Trials of Three Multi‑Stage U‑VLP Malaria Vaccine Candidates – First‑in‑Human Study of LYB014, LYB017 and LYB027 Set to Begin in Australia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now